Abstract
Diabetes mellitus is a risk factor for the development of coronary artery disease and chronic heart failure. When carefully screened for, diabetes or prediabetic disorders, are present in the majority of patients with clinically manifest ischaemic heart disease, and confer a major adverse impact upon morbidity and mortality. Important therapeutic modifications are required in the management of coronary artery disease and chronic heart failure associated with diabetes, and vice versa. However, despite optimal management, aided by recent landmark trials solely recruiting patients with diabetes, outcomes for patients with diabetes and heart disease remain poor. This review outlines the epidemiology, pathogenesis and management of diabetic heart disease, along with highlighting the many gaps in the evidence-base and suggesting future research priorities.
© 2012 Blackwell Publishing Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin Receptor Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Blood Glucose / metabolism
-
Cardiac Resynchronization Therapy / methods
-
Coronary Artery Disease / etiology*
-
Coronary Artery Disease / therapy
-
Diabetic Angiopathies / etiology*
-
Diabetic Angiopathies / therapy
-
Diuretics / therapeutic use
-
Heart Failure / etiology*
-
Heart Failure / therapy
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Life Style
-
Mineralocorticoid Receptor Antagonists / therapeutic use
-
Myocardial Revascularization
-
Platelet Aggregation Inhibitors / therapeutic use
-
Prognosis
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Blood Glucose
-
Diuretics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Mineralocorticoid Receptor Antagonists
-
Platelet Aggregation Inhibitors